<DOC>
	<DOCNO>NCT00301782</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , vincristine , bleomycin , carboplatin , etoposide phosphate , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . It yet know combination chemotherapy regimen effective treat germ cell tumor . PURPOSE : This randomized phase II trial study two different combination chemotherapy regimens compare well work treat male patient germ cell tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Male Patients With Germ Cell Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare response rate patient poor-prognosis extracranial nonseminoma germ cell tumor treat intensive induction chemotherapy comprise cisplatin , vincristine , bleomycin , carboplatin follow bleomycin , etoposide phosphate , cisplatin ( BEP ) v standard BEP chemotherapy . Secondary - Compare overall progression-free survival patient treat regimen . - Compare toxicity regimens patient . OUTLINE : This multicenter , open-label , randomize study . Patients stratify accord participate center , pre-protocol low-dose chemotherapy ( yes v ) , clinically important factor . Patients randomize 1 2 treatment arm . - Arm I ( BEP ) : Patients receive bleomycin IV 15 minute day 1 2 day 8 15 etoposide phosphate IV 1 hour cisplatin IV 4 hour day 1-5 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . - Arm II ( CBOP/BEP ) : Patients receive chemotherapy accord follow schedule : - Weeks 1-6 : Patients receive cisplatin IV 6 hour day 1 , 2 , 8 , 15 , 16 , 22 ( OR 4 hour day 1-5 15-19 ) ; vincristine IV day 1 , 8 , 15 , 22 , 29 , 36 ; bleomycin IV 15 minute day 1 , 15 , 29 , 36 bleomycin IV continuously day 8-12 22-25 ; carboplatin IV 30-60 minute day 8 22 . - Weeks 7-15 : Patients receive bleomycin IV continuously day 1-5 , 8-12 , 15-19 etoposide phosphate IV 1 hour cisplatin IV 4 hour day 1-5 . Treatment repeat every 21 day 4 course . After completion study treatment , patient follow periodically 5 year . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 88 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Teratoma</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Nonseminoma germ cell tumor extracranial primary site diagnose 1 follow method : Histologic confirmation Alphafetoprotein ( AFP ) &gt; 1,000 ng/mL human chorionic gonadotropin ( hCG ) &gt; 5,000 IU/L appropriate clinical picture man &lt; 45 year age Poor prognosis feature define â‰¥ 1 following : AFP &gt; 10,000 ng/mL hCG &gt; 50,000 IU/L Lactic dehydrogenase &gt; 10 time normal Nonpulmonary visceral metastasis Mediastinal primary site PATIENT CHARACTERISTICS : Male WHO performance status 03 Glomerular filtration rate &gt; 50 mL/min Less 50 mL/min eligible due obstructive neuropathy relieve stenting nephrostomy No comorbid condition would prevent treatment Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior chemotherapy except lowdose chemotherapy stabilize disease study therapy</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>testicular choriocarcinoma embryonal carcinoma</keyword>
	<keyword>testicular choriocarcinoma teratoma</keyword>
	<keyword>testicular choriocarcinoma yolk sac tumor</keyword>
	<keyword>testicular choriocarcinoma</keyword>
	<keyword>testicular embryonal carcinoma teratoma</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor</keyword>
	<keyword>testicular embryonal carcinoma</keyword>
	<keyword>testicular yolk sac tumor</keyword>
	<keyword>testicular yolk sac tumor teratoma</keyword>
	<keyword>stage I malignant testicular germ cell tumor</keyword>
	<keyword>stage II malignant testicular germ cell tumor</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>recurrent extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>stage I extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>stage II extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>stage III extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>stage IV extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>recurrent extragonadal germ cell tumor</keyword>
	<keyword>testicular immature teratoma</keyword>
	<keyword>testicular mature teratoma</keyword>
	<keyword>adult teratoma</keyword>
</DOC>